108 related articles for article (PubMed ID: 16816919)
21. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
22. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
24. Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.
Cho ES; Yu JH; Kim MS; Yim M
Yonsei Med J; 2005 Feb; 46(1):149-54. PubMed ID: 15744818
[TBL] [Abstract][Full Text] [Related]
25. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
26. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
[TBL] [Abstract][Full Text] [Related]
27. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
28. Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.
Soares AC; Souza DG; Pinho V; Vieira AT; Barsante MM; Nicoli JR; Teixeira M
Br J Pharmacol; 2003 Nov; 140(5):855-62. PubMed ID: 14585803
[TBL] [Abstract][Full Text] [Related]
29. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
30. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
[TBL] [Abstract][Full Text] [Related]
31. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
32. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
Kanes SJ; Tokarczyk J; Siegel SJ; Bilker W; Abel T; Kelly MP
Neuroscience; 2007 Jan; 144(1):239-46. PubMed ID: 17081698
[TBL] [Abstract][Full Text] [Related]
33. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.
Zhang HT; Huang Y; Jin SL; Frith SA; Suvarna N; Conti M; O'Donnell JM
Neuropsychopharmacology; 2002 Oct; 27(4):587-95. PubMed ID: 12377395
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Marko D; Romanakis K; Zankl H; Fürstenberger G; Steinbauer B; Eisenbrand G
Cell Biochem Biophys; 1998; 28(2-3):75-101. PubMed ID: 9515161
[TBL] [Abstract][Full Text] [Related]
35. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
Brage M; Lie A; Ransjö M; Kasprzykowski F; Kasprzykowska R; Abrahamson M; Grubb A; Lerner UH
Bone; 2004 Mar; 34(3):412-24. PubMed ID: 15003789
[TBL] [Abstract][Full Text] [Related]
36. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
37. Effects of continuous calcitonin treatment on osteoclast-like cell development and calcitonin receptor expression in mouse bone marrow cultures.
Ikegame M; Rakopoulos M; Martin TJ; Moseley JM; Findlay DM
J Bone Miner Res; 1996 Apr; 11(4):456-65. PubMed ID: 8992876
[TBL] [Abstract][Full Text] [Related]
38. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Kyoi T; Noda K; Oka M; Ukai Y
Life Sci; 2004 Nov; 76(1):71-83. PubMed ID: 15501481
[TBL] [Abstract][Full Text] [Related]
39. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F
Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801
[TBL] [Abstract][Full Text] [Related]
40. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils.
Liu J; Muñoz NM; Meliton AY; Zhu X; Lambertino AT; Xu C; Myo S; Myou S; Boetticher E; Johnson M; Leff AR
Pulm Pharmacol Ther; 2004; 17(2):73-9. PubMed ID: 15123228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
